<DOC>
	<DOCNO>NCT02955069</DOCNO>
	<brief_summary>This study investigate efficacy safety PDR001 patient advance metastatic non-functional neuroendocrine tumor pancreatic , gastrointestinal ( GI ) , thoracic origin</brief_summary>
	<brief_title>Study Efficacy Safety PDR001 Patients With Advanced Metastatic Non-functional Neuroendocrine Tumors Pancreatic , Gastrointestinal ( GI ) , Thoracic Origin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>Pathologically confirm , welldifferentiated advanced , nonfunctional neuroendocrine tumor GI , pancreatic thoracic origin . No history , active symptom relate carcinoid syndrome . Patients must pretreated advanced disease number prior systemic therapy/regimen depend origin . Patients must willing provide biopsy material . Radiological documentation disease progression on/or last treatment ; progression must observe within 6 month prior start study treatment Poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoid , large cell neuroendocrine carcinoma small cell carcinoma . Pretreatment interferon last treatment prior start study treatment . Prior treatment study indication : Antibodies immunotherapy within 6 week first dose study treatment . PRRT administer within 6 month first dose . Systemic antineoplastic therapy Tyrosine kinase inhibitor within 14 day 5 halflives , whichever longer , first dose study treatment . Prior PD1 PDL1directed therapy . Cryoablation , radiofrequency ablation , transarterial chemoembolization hepatic metastasis History severe hypersensitivity reaction monoclonal antibody opinion investigator may pose increase risk serious infusion reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced metastatic</keyword>
	<keyword>NET</keyword>
	<keyword>pNET</keyword>
	<keyword>GI NET</keyword>
	<keyword>thoracic NET</keyword>
</DOC>